椎間板変性症治療薬の世界市場2022

【英語タイトル】Degenerative Disc Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Global Markets Directが出版した調査資料(GMDHC22071IDB)・商品コード:GMDHC22071IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2022年3月
・ページ数:62
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥280,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥560,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥840,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
本調査レポートでは、開発中の椎間板変性症治療薬市場について調査・分析し、椎間板変性症概要、治療薬開発、パイプライン概要、企業別のパイプライン、企業別の開発中製品、治療薬分析、標的別分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。
・椎間板変性症-概要
・椎間板変性症-治療薬開発
・パイプライン概要
・企業別のパイプライン
・企業別の開発中製品
・椎間板変性症-治療薬分析
・標的別分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・椎間板変性症-治療薬開発に携わる企業
【レポートの概要】

Degenerative Disc Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 3, 2, 6, 2 and 1 respectively.

Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Degenerative Disc Disease – Overview
Degenerative Disc Disease – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Degenerative Disc Disease – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Degenerative Disc Disease – Companies Involved in Therapeutics Development
Amplicore Inc
AnGes Inc
Angitia Biopharmaceuticals
Bone Therapeutics SA
CHA Biotech Co Ltd
DiscGenics Inc
FibroGenesis LLC
Genequine Biotherapeutics GmbH
Histogen Inc
Kolon TissueGene Inc
Locate Bio Ltd
Notogen Inc
Rudacure Co Ltd
Spine BioPharma LLC
Stayble Therapeutics AB
Techfields Pharma Co Ltd
U.S. Stem Cell Inc
Xalud Therapeutics Inc
Degenerative Disc Disease – Drug Profiles
AdipoCell – Drug Profile
Product Description
Mechanism Of Action
AGA-111 – Drug Profile
Product Description
Mechanism Of Action
ALLOB – Drug Profile
Product Description
Mechanism Of Action
History of Events
AM-2101 – Drug Profile
Product Description
Mechanism Of Action
AMG-0101 – Drug Profile
Product Description
Mechanism Of Action
History of Events
AMG-0103 – Drug Profile
Product Description
Mechanism Of Action
History of Events
CBAC-01 – Drug Profile
Product Description
Mechanism Of Action
CBAC-03 – Drug Profile
Product Description
Mechanism Of Action
Cell Therapy for Degenerative Disc Disease and Spinal Cord Injury – Drug Profile
Product Description
Mechanism Of Action
CybroCell – Drug Profile
Product Description
Mechanism Of Action
GQ-401 – Drug Profile
Product Description
Mechanism Of Action
HST-004 – Drug Profile
Product Description
Mechanism Of Action
History of Events
LB-002 – Drug Profile
Product Description
Mechanism Of Action
NTG-101 – Drug Profile
Product Description
Mechanism Of Action
History of Events
rebonuputemcel – Drug Profile
Product Description
Mechanism Of Action
History of Events
Remedisc – Drug Profile
Product Description
Mechanism Of Action
History of Events
STA-363 – Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy 1 for Degenerative Disc Disease – Drug Profile
Product Description
Mechanism Of Action
Stem Cell Therapy for Degenerative Disc Disease – Drug Profile
Product Description
Mechanism Of Action
TG-D – Drug Profile
Product Description
Mechanism Of Action
X-0002 – Drug Profile
Product Description
Mechanism Of Action
XT-150 – Drug Profile
Product Description
Mechanism Of Action
Degenerative Disc Disease – Dormant Projects
Degenerative Disc Disease – Product Development Milestones
Featured News & Press Releases
May 14, 2020: Histogen publishes preclinical data on its HST 004 spinal disc program
Nov 14, 2018: Therapeutic potential of NTG-101, a single dose injectable treatment for Degenerative Disc Disease, demonstrated in preclinical large animal study published in Nature Publishing Group’s “Scientific Reports”
Mar 20, 2018: USRM Chief Science Officer to Present at Paleo f(x) Ancestral Healing Conference in Austin, Texas
Feb 28, 2018: USRM Chief Science Officer to Present at Academy of Regenerative Practices Conference
Jan 15, 2018: USRM Reaches Key Sales Milestone of Proprietary Adipocell Product
Nov 28, 2017: Degenerative Disc Patients Significantly Improve With USRM’s Adipocell
Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study
Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference
Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Degenerative Disc Disease, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Degenerative Disc Disease - Pipeline by Amplicore Inc, 2022
Degenerative Disc Disease - Pipeline by AnGes Inc, 2022
Degenerative Disc Disease - Pipeline by Angitia Biopharmaceuticals, 2022
Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, 2022
Degenerative Disc Disease - Pipeline by CHA Biotech Co Ltd, 2022
Degenerative Disc Disease - Pipeline by DiscGenics Inc, 2022
Degenerative Disc Disease - Pipeline by FibroGenesis LLC, 2022
Degenerative Disc Disease - Pipeline by Genequine Biotherapeutics GmbH, 2022
Degenerative Disc Disease - Pipeline by Histogen Inc, 2022
Degenerative Disc Disease - Pipeline by Kolon TissueGene Inc, 2022
Degenerative Disc Disease - Pipeline by Locate Bio Ltd, 2022
Degenerative Disc Disease - Pipeline by Notogen Inc, 2022
Degenerative Disc Disease - Pipeline by Rudacure Co Ltd, 2022
Degenerative Disc Disease - Pipeline by Spine BioPharma LLC, 2022
Degenerative Disc Disease - Pipeline by Stayble Therapeutics AB, 2022
Degenerative Disc Disease - Pipeline by Techfields Pharma Co Ltd, 2022
Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, 2022
Degenerative Disc Disease - Pipeline by Xalud Therapeutics Inc, 2022
Degenerative Disc Disease - Dormant Projects, 2022

List of Figures
Number of Products under Development for Degenerative Disc Disease, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

★調査レポート[椎間板変性症治療薬の世界市場2022] (コード:GMDHC22071IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[椎間板変性症治療薬の世界市場2022]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆